Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
439.00    -1.00 (-0.23%)
Bid:
433.50
Ask:
439.00
Spread: 5.50 (1.269%)
Market Cap: £215.91m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Trading Update and Interim Management Statement

23 Oct 2013 07:00

RNS Number : 1453R
Zotefoams PLC
23 October 2013
 



23 October 2013

 

 

Zotefoams plc

("Zotefoams" or "the Company")

 

Trading Update and Interim Management Statement for the Quarter ended 30 September 2013

 

Zotefoams plc (the "Company"), a world leader in cellular material technology, today announces a trading update and its interim management statement for the third quarter ended 30 September 2013.

Growth in sales of High-Performance Products ("HPP") products and Azote® polyolefin foams in Asia in the third quarter has been offset by an unexpected shortfall in shipments to some European polyolefin customers, leaving total sales in the quarter at the same level as 2012 and below the level previously anticipated. These falls are, in the main, related to larger customers who are responding to continued destocking in the downstream market, which affects their demand levels in the short-term. The Board considers it prudent to assume that this trend will continue for the remainder of the year but, with the benefit of our shorter lead times, we expect to progress in this market in 2014.

Our HPP products business continues to grow strongly with long-term projects giving positive momentum into 2014 and beyond.

MuCell Extrusion, our technology licensing business, is focusing increasingly on consumer packaging. Given the scale of this opportunity further investment in our technology is being made during the fourth quarter.

Foreign currency rates have been less favourable in the third quarter compared to the first half of 2013 and the adverse impact in this period, mainly due to our US-dollar denominated investments, is in the region of £0.4 million.

The overall impact of these factors is that the Company expects second half profit to be below the level seen in the first half and therefore profit for the year to be below previous management expectations.

Although it is disappointing to see the current shortfall in European polyolefin foams, the Board considers the impact to be short-term and is encouraged by the performance of the business elsewhere. A return to growth is expected in 2014, and the Board remains confident in the long-term prospects for the business.

 

 

Enquiries:

Zotefoams plc

0208-664-1600

David Stirling, Managing Director

Clifford Hurst, Finance Director

FTI Consulting

0207-831-3113

John Dineen, Victoria Foster Mitchell

 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular material technology. Using a unique manufacturing process with environmentally friendly nitrogen expansion, Zotefoams produces lightweight foams in Croydon, UK and Kentucky, USA for diverse markets worldwide through its global sales force. Zotefoams also owns and licenses patented MuCell® microcellular foam technology from a base in Massachusetts, USA to customers worldwide and sells T-Tubes® advanced insulation systems made from its patented ZOTEK® fluoropolymer foams.

 

www.zotefoams.com

 

ZOTEK®, Azote® and microZOTE® are registered trademarks of Zotefoams plc. MuCell® is a registered trademark of Trexel Inc. T-Tubes® is a registered trademark of UFP Technologies Inc.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCMTBRTMBBTBJJ
Date   Source Headline
20th Jul 20224:36 pmRNSPrice Monitoring Extension
12th Jul 202212:39 pmRNSDirector/PDMR Shareholding
8th Jul 20227:00 amRNSNotice of Results
30th Jun 20224:52 pmRNSDirector/PDMR Shareholding
8th Jun 20224:40 pmRNSSecond Price Monitoring Extn
8th Jun 20224:35 pmRNSPrice Monitoring Extension
8th Jun 20228:49 amRNSDirector/PDMR Shareholding
26th May 20224:41 pmRNSSecond Price Monitoring Extn
26th May 20224:36 pmRNSPrice Monitoring Extension
25th May 20221:04 pmRNSResult of the 2022 Annual General Meeting
25th May 20227:00 amRNSTrading Update
18th May 20224:41 pmRNSSecond Price Monitoring Extn
18th May 20224:36 pmRNSPrice Monitoring Extension
12th May 20223:58 pmRNSDirector/PDMR Shareholding
11th May 20222:13 pmRNSDirector/PDMR Shareholding
25th Apr 20225:16 pmRNSDirector/PDMR Shareholding
25th Apr 20227:00 amRNS2021 Annual Report and Notice of the 2022 AGM
11th Apr 20223:49 pmRNSDirector/PDMR Shareholding
22nd Mar 20227:00 amRNSPreliminary Results
14th Mar 202212:30 pmRNSDirector/PDMR Shareholding
25th Feb 20227:00 amRNSNotice of results and investor presentation
15th Feb 20224:26 pmRNSDirector/PDMR Shareholding
27th Jan 20227:00 amRNSFull Year Trading Update
12th Jan 202211:12 amRNSDirector/PDMR Shareholding
23rd Dec 20211:56 pmRNSDirector/PDMR Shareholding
17th Dec 20217:00 amRNSTrading Update
14th Dec 202111:55 amRNSDirector/PDMR Shareholding
12th Nov 202112:41 pmRNSDirector/PDMR Shareholding
10th Nov 20215:48 pmRNSHolding(s) in Company
4th Nov 20215:59 pmRNSHolding(s) in Company
4th Nov 20213:31 pmRNSDirector/PDMR Shareholding
3rd Nov 20217:00 amRNSQ3 Trading Update
15th Oct 202112:10 pmRNSDirector/PDMR Shareholding
12th Oct 202111:05 amRNSDirector/PDMR Shareholding
1st Oct 20213:31 pmRNSHolding(s) in Company
14th Sep 202110:05 amRNSDirector/PDMR Shareholding
12th Aug 20212:28 pmRNSDirector/PDMR Shareholding
10th Aug 20217:00 amRNSInterim Results
19th Jul 20219:26 amRNSNotice of Results
13th Jul 20211:59 pmRNSDirector/PDMR Shareholding
14th Jun 20213:06 pmRNSDirector/PDMR Shareholding
14th Jun 202111:35 amRNSDirector/PDMR Shareholding
10th Jun 20214:41 pmRNSDirector/PDMR Shareholding
9th Jun 20213:48 pmRNSDirector/PDMR Shareholding
2nd Jun 20213:49 pmRNSHolding(s) in Company
26th May 202112:08 pmRNSResult of AGM
26th May 20217:00 amRNSTrading Update
12th May 20213:44 pmRNSDirector/PDMR Shareholding
28th Apr 20212:05 pmRNSDirector/PDMR Shareholding
26th Apr 20213:16 pmRNS2020 Annual Report, Notice of the 2021 AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.